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Abstract 
Rationale: Pretargeted radioimmunotherapy (PRIT) based upon bioorthogonal click chemistry has been investigated 
for the first time in the context of peritoneal carcinomatosis using a CEA-targeting 35A7 mAb bearing 
trans-cyclooctene (TCO) moieties and several 177Lu-labeled tetrazine (Tz) radioligands. Starting from three Tz probes 
containing PEG linkers of varying lengths between the DOTA and Tz groups (i.e. PEGn = 3, 7, or 11, respectively, for 
Tz-1, Tz-2, and Tz-3), we selected [177Lu]Lu-Tz-2 as the most appropriate for pretargeted SPECT imaging and 
demonstrated its efficacy in tumor growth control. Methods: An orthotopic model of peritoneal carcinomatosis (PC) 
was obtained following the intraperitoneal (i.p.) injection of A431-CEA-Luc cells in nude mice. Tumor growth was 
assessed using bioluminescence imaging. Anti-CEA 35A7 mAb was grafted with 2-3 TCO per immunoglobulin. 
Pretargeted SPECT imaging and biodistribution experiments were performed to quantify the activity concentrations 
of [177Lu]Lu-Tz-1-3 in tumors and non-target organs to determine the optimal Tz probe for the PRIT of PC. Results: 
The pharmacokinetic profiles of [177Lu]Lu-Tz-1-3 alone were determined using both SPECT imaging and 
biodistribution experiments. These data revealed that [177Lu]Lu-Tz-1 was cleared via both the renal and hepatic 
systems, while [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3 were predominantly excreted via the renal system. In addition, 
these results illuminated that the longer the PEG linker, the more rapidly the Tz radioligand was cleared from the 
peritoneal cavity. The absorbed radiation dose corresponding to pretargeting with 35A7-TCO followed 24 h later by 
[177Lu]Lu-Tz-1-4 was higher for tumors following the administration of [177Lu]Lu-Tz-2 (i.e. 0.59 Gy/MBq) compared to 
either [177Lu]Lu-Tz-1 (i.e. 0.25 Gy/MBq) and [177Lu]Lu-Tz-3 (i.e. 0.18 Gy/MBq). In a longitudinal PRIT study, we 
showed that the i.p. injection of 40 MBq of [177Lu]Lu-Tz-2 24 hours after the systemic administration of 35A7-TCO 
significantly slowed tumor growth compared to control mice receiving only saline or 40 MBq of [177Lu]Lu-Tz-2 alone. 
Ex vivo measurement of the peritoneal carcinomatosis index (PCI) confirmed that PRIT significantly reduced tumor 
growth (PCI = 15.5 ± 2.3 after PRIT vs 30.0 ± 2.3 and 30.8 ± 1.4 for the NaCl and [177Lu]Lu-Tz-2 alone groups, 
respectively). Conclusion: Our results clearly demonstrate the impact of the length of PEG linkers upon the 
biodistribution profiles of 177Lu-labeled Tz radioligands. Furthermore, we demonstrated for the first time the 
possibility of using bioorthogonal chemistry for both the pretargeted SPECT and PRIT of peritoneal carcinomatosis. 
Key words: Pretargeting, bioorthogonal chemistry, peritoneal carcinomatosis, therapy, SPECT-CT imaging 
Introduction 
Radioimmunotherapy (RIT) is an effective 
approach for the treatment of non-solid tumors  
such as non-Hodgkin lymphomas [1]  that increases 
overall survival in patients exhibiting 
chemoresistance to tyrosine kinase inhibitors. 
However, the clinical use of RIT remains limited for 
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solid tumors because of the low penetration of 
radiolabeled monoclonal antibodies (mAbs) and the 
hematotoxicity caused by their long half-life in the 
blood [2]. To circumvent these drawbacks, 
pretargeted radioimmunotherapy (PRIT) strategies 
have been developed that are predicted on the 
administration of the radiolabeled probe and the mAb 
in two distinct steps [3].  
The oldest PRIT approaches, including systems 
based on (strept)avidin-biotin [4] and bispecific 
antibodies (bsAbs) [5], have been evaluated in clinical 
trials. Unlike the (strept)avidin-biotin system  
which demonstrated significant toxicity due to the 
immunogenicity of (strept)avidin as well as its 
non-specific interaction with endogenous biotin [6]  
the bsAb-based approach has successfully reached 
phase II/III trials [7]. Nonetheless, bsAbs remain 
difficult to engineer, limiting their widespread clinical 
implementation. Other systems relying on the use of 
oligonucleotides (including phosphorodiamidate 
morpholinos (MORFs) and peptide nucleic acids 
(PNAs) [8]) have attracted interest for in vivo imaging 
[9,10], but significant non-specific uptake in both the 
kidneys and liver impedes their clinical translation.  
The most recently developed approach to PRIT 
uses bioorthogonal chemistry to facilitate the in vivo 
ligation of mAbs and radiolabeled probes through the 
formation of a covalent bond between two entities 
[11]. The term ‘bioorthogonal’ is used to describe 
chemical reactions that occur under physiological 
conditions in vitro and in vivo (pH and temperature) 
without interfering with biological molecules. Of the 
various bioorthogonal reactions that have been 
studied over the past two decades, the 
inverse-electron demand Diels-Alder cycloaddition 
(IEDDA) is the most rapid, with high second order 
rate constants ranging from 103 to 106 M-1s-1  [12,13]. 
The IEDDA cycloaddition occurs between a 
dienophile such as a trans-cyclooctene (TCO) and a 
diene like 1,2,4,5-tetrazine (Tz), leading to the 
formation of a covalent cycloadduct [11]. Pretargeting 
using IEDDA has been successfully applied to both 
PET/SPECT imaging and PRIT in mice bearing 
subcutaneous tumors [14–18]. However, to the best of 
our knowledge, no one has reported the use of this 
approach to pretargeting in disseminated tumors.  
Colorectal cancer (CRC) represents the third 
most common cancer in the world and is associated 
with a high propensity to generate liver, lung, and 
peritoneal metastases [19,20]. Peritoneal 
carcinomatosis (PC) is characterized by the 
progressive invasion of the peritoneal cavity by 
tumors of various origins, such as ovarian, colorectal, 
gastric, and, less frequently, non-digestive cancers 
[21]. Metastatic CRC leads to a PC in about 30% of 
cases, considering both synchronous and 
metachronous diseases [22] and is often associated 
with poor prognosis [23]. The therapeutic regimen for 
PC consists of surgery that can be associated with 
chemotherapy administrated either systemically or 
intraperitoneally [23]. In addition, heated 
chemotherapy applied in the peritoneal cavity 
intra-operatively (hyperthermic intraperitoneal 
chemotherapy; HIPEC) can potentiate the absorption 
of cytotoxic drugs [24,25]. 
Despite improvements to the median and overall 
survival times obtained by combining cytoreductive 
surgery and HIPEC, both direct morbidity and 
general mortality remain high, suggesting that the 
therapy of PC needs to be optimized [26]. RIT of 
metastatic CRC has already demonstrated some 
effectiveness in preclinical models [27–30]. 
Furthermore, a recent protocol consisting of briefly 
administering RIT intraperitoneally showed 
significant efficacy for tumor growth control [31,32]. 
Based on these data, we assume that an innovative 
approach to PRIT featuring the local intraperitoneal 
injection of a radiolabeled Tz can be harnessed to 
increase the efficacy of the treatment of PC.  
In the present study, pretargeting was conducted 
in mice bearing orthotopic tumors (A431-CEA-Luc 
cells) with a non-internalizing anti-CEA mAb (35A7) 
[33] in conjunction with several different Tz probes 
radiolabeled with lutetium-177 (half-life of 6.65 days, 
Maximal β- energy of 498.3 keV). Three different 
Tz-based probes (Table 1, [177Lu]Lu-Tz-1-3) were 
assessed in vivo via both SPECT imaging and 
biodistribution experiments in order to determine the 
influence of the PEG linker length on their 
pharmacokinetic and dosimetric profiles. The 
performance of these three probes was then compared 
to that of [177Lu]Lu-Tz-4, which has already 
demonstrated impressive results in the PRIT of 
subcutaneous models of pancreatic cancer and CRC 
[17,18]. Based on these biodistribution data, a PRIT 
study was next conducted with [177Lu]Lu-Tz-2. Both 
in vivo bioluminescence imaging and the ex vivo 
determination of the peritoneal carcinomatosis index 
(PCI) revealed a significant slow-down of tumor 
growth in the treated mice compared to control 
cohorts. We thus successfully performed the first 
proof-of-concept pretargeted SPECT imaging and 
PRIT of PC using the IEDDA cycloaddition. 
Materials and Methods  
Cell line and antibody. The A431-CEA-Luc is 
derived from vulvar squamous epithelial carcinoma 
and was transfected with constructs encoding for both 
carcinoembryonic antigen (CEA) and luciferase. CEA 
is highly expressed in human colon carcinoma [34,35]. 
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Thus, the abilities of the A431-CEA-Luc cell line to 
express CEA and disseminate when injected 
intraperitoneally in nude mice make it a suitable 
model for mimicking colorectal peritoneal 
carcinomatosis [33,36]. A431-CEA-Luc cells and the 
non-internalizing murine anti-CEA mAb 35A7 (IgG1) 
were both provided by Dr. J-P. Pouget and Dr. I. 
Navarro-Teulon (IRCM, Inserm, Montpellier, France) 
[33]. The cell line was maintained at 37 °C with 5% 
CO2 in humidified environment in Dulbecco’s 
Modified Eagle F12 Medium supplemented with 10% 
foetal serum, 1% penicillin/streptomycin and 
extemporaneously with 1% geneticin, 1% 
hygromycin. 
mAb-TCO conjugation. The conjugation of 
TCO-NHS to 35A7 was performed as previously 
described [37]. The quantification of the number of 
TCO moieties grafted per mAb was determined by 
Matrix Assisted Laser Desorption Ionization 
Time-of-Flight (MALDI-TOF) mass spectrometry, 
carried out on a MALDI-TOF/TOF Autoflex Speed 
(Bruker Daltonics). Sample preparation, sample 
deposits on the MALDI-TOF target, calibration, and 
treatment of spectra were performed as previously 
described [37]. Spectrum acquisition was performed 
in the positive linear ion mode with an ion source 
voltage of 19.00 kV, a laser power of 75% and 
smart-beam set at 1 minimum with a frequency of 
1000 Hz. A number of 1000 shots was averaged for 
each spectrum, in the mass-range between 30 and 210 
kDa.  
Tz Syntheses. Tz-4 was kindly provided by Dr. B. 
M. Zeglis and Dr. R. Membreno (Hunter College, New 
York, USA) [18]. The syntheses of Tz-1-3 are detailed 
in the Supplementary Information.  
Radiolabeling. Tz-4 was radiolabeled with 
lutetium-177 as previously described [18]. For Tz-1 
and Tz-2, two different radiolabeling methods were 
assessed (i.e. Method A and Method B), while Tz-3 
was radiolabeled using only Method B. The first 
biodistribution experiment with Tz-1 was performed 
using radiotracer synthesized using Method A, while 
the second biodistribution experiment comparing 
Tz-1-4 as well as the therapy study with Tz-2 were 
performed using radiotracers synthesized using 
Method B. Both radiolabeling methods are detailed in 
the Supplementary Information.  
Animals. This investigation conforms to the 
Guide for Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication 
n°85-236, revised 1996). In addition, all experiments 
were performed in accordance with the relevant 
guidelines and regulations and were approved by 
both the local Ethic committee of Clermont-Ferrand 
(CEMEAA n°002) and the French Ministry of 
Education and Research (approval 
n°5103-2016042010209100). A total of 138 female mice 
(Nude NMRI Foxn1nu/Foxn1nu) acquired from Janvier 
Labs (Le Genest-Saint-Isles, France) were used for the 
whole experiments. Mice (5 weeks old, median weight 
 
Table 1: Structures and properties of [177Lu]Lu-Tz-1-4. Am: molar activity. 
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22 g) were housed in standard conditions (n = 5 per 
cage) in ventilated racks with a 21-24 °C environment 
with 60% humidity and a 12 h light / 12 h dark cycle 
with access to food and water ad libitum. All i.v. 
injections were made in the lateral tail vein of vigil 
mice via the dilatation of veins using cotton dipped in 
hot water to avoid the photochemical isomerization of 
TCO to cis-cyclooctene (CCO). All i.p. injections were 
made on vigil mice in the lower right quadrant of the 
abdomen. For in vivo imaging, mice were placed 
under general gas anesthesia receiving isoflurane at 
2.5% in oxygen highly enriched air (90%) (Minerve, 
France). Euthanasia was performed by cervical 
dislocation after isoflurane gas overdose.  
Biodistributions studies. Prior to 
biodistribution experiments, mice were i.p. 
xenografted with 1×106/ 250 µL A431-CEA-Luc cells. 
Tumor growth was monitored one day after the graft 
and 3 days before the graft using bioluminescence 
imaging via the i.p. injection of 15 mg/mL of luciferin 
(IVIS Spectrum, PerkinElmer, France). Twenty-one 
days after the graft, the mice were randomly assigned 
to a protocol group.  
Biodistribution of [177Lu]Lu-Tz-1-3. 9 mice were 
randomly divided into three groups (n = 3 per group) 
and were then injected i.p. with 10 MBq of 
[177Lu]Lu-Tz-1, [177Lu]Lu-Tz-2, or [177Lu]Lu-Tz-3. At 2 
h and 24 h after the injection of [177Lu]Lu-Tz-1-3, the 
mice were imaged via SPECT-CT. The mice were then 
sacrificed 24 h post injections, and the relevant organs 
were harvested for gamma counting.  
Selection of the Most Appropriate Tz Radiotracer. 54 
mice were divided into 4 groups (n = 9 or 18 per 
group) and then injected i.p. with 50 µg of 35A7-TCO 
(≈ 3-4 TCO per mAb), followed 24 h later by the 
injection of [177Lu]Lu-Tz-1-4. Mice were then 
sacrificed at 24, 48, and 144 h after the administration 
of the radioligand, and their main organs were 
harvested for gamma counting.  
SPECT-CT Imaging. Multimodal SPECT-CT 
imaging was performed using a NanoScan 
SPECT/CT camera (Mediso Ltd) equipped with four 
detectors and multi pinhole collimation (APT62). 
Nucline software (Mediso Ltd) was used for image 
acquisitions and reconstructions (Nucline 3.00.018). 
CT parameters were as following: helical scan with 
480 projections (300 ms per projection), 50 kV, 590 uA, 
pitch 1.0, binning 1:4 and field of view: max. SPECT 
images were acquired within the CT scan range with a 
standard resolution. The time per projection was 
determined in accordance with the detected 
radioactivity (most frequently used: 30 seconds). Mice 
were placed in a Multicell Mouse L bed (Mediso Ltd) 
with temperature control (37 °C). SPECT-CT imaging 
was performed on representative mice (n= 2 or 3) of 
each group at different time points (i.e. 2, 24, 48, and 
72 h) after the injection of [177Lu]Lu-Tz-1-3. SPECT 
image reconstruction was conducted using 
TeraTomo3D (Nucline v3.00.018) with normal 
dynamic range. Regularization filters, reconstruction 
resolution, and iterations were set to “medium”. 
Additional corrections were performed during 
reconstruction: Monte Carlo correction quality was set 
to “high”; Attenuation: based on CT attenuation map 
and scatter corrections; Activity decay correction: 
during acquisition time lapse.  
Dosimetry. Absorbed doses to organs were 
calculated for [177Lu]Lu-Tz-1-4 following the MIRD 
methodology [38]. Self S values, calculated using 
GATE Monte Carlo simulations [39–41], were 
extracted from a previous study [42] on same mouse 
models for heart, lungs, liver, kidneys, and spleen. In 
addition, a specific self S value calculation was 
performed for a spherical tumor with a mean weight 
of 0.015 g and a corresponding diameter of 3 mm. As 
the mean energy of electrons emitted from the beta 
decay of [177Lu] is 133.3 keV, their mean range (0.2 
mm) in soft tissues is very small compared to the 
mouse organ sizes, therefore only self S values have 
been considered in this study.  
Pretargeted radioimmunotherapy. Throughout 
the duration of the experiment, mice were housed 
individually in armored enclosures with 12 h light / 
12 h dark cycles and were provided access to food and 
water ad libitum. Nine days after inoculation, the mice 
were blindly assigned to 3 groups (n = 6 per group). 
One group was first injected i.v. with 50 µg / 150 µL 
of 35A7-TCO (≈ 3-4 TCO per mAb) followed 24 h later 
by the i.p. administration of 40 MBq / 250 µL of 
[177Lu]Lu-Tz-2. The two other groups were first 
injected i.v. with 150 µL of 0.9% NaCl, followed 24 h 
later by the i.p. administration of either 250 µL of 0.9% 
NaCl or 40 MBq/ 250 µL of [177Lu]Lu-Tz-2. The 
longitudinal PRIT study was conducted in a 
double-blind manner to avoid any bias.  
Tumor growth assessment. Tumor growth was 
monitored using bioluminescence imaging one day 
after xenografting, one day before the first injections, 
and once a week until the sacrifice of each mouse. 
Mice were sacrificed in the event of weight loss (≥ 
20%), behavioral changes, and the appearance of 
clinical signs such as anemia, pain, or palpable tumor 
mass on the abdomen. All observations were reported 
in a score grid (i.e. absence, moderate, severe 
annotations), and the mice were sacrificed when the 
maximal ethical disease activity index was reached. 
Monitoring could not be performed after 20 days of 
tumor growth due to the lack of linearity between the 
bioluminescence signal and tumor size [33].   
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Scheme 1: Experimental protocol for determining the biodistribution profiles [177Lu]Lu-Tz-1-4 upon in vivo pretargeting with 35A7-TCO. The same protocol was applied to 
interrogate the biodistribution profiles of [177Lu]Lu-Tz-1-3 alone, except in these cases, the i.p. injections were made at day 21 post-xenograft, as there was no injection of 
35A7-TCO. 
 
Scheme 2: Experimental protocol for the longitudinal PRIT study with 35A7-TCO and [177Lu]Lu-Tz-2. 
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PCI determination. We performed the PCI  a 
standard method allowing quantifying the number of 
peritoneal tumors through the attribution of a score 
ranging from 1 to 39, which correlates the severity of 
the disease  during mice necropsy. PCI was 
determined according to the score method described 
by Sugarbaker [24] and adapted for rodents by Klaver 
et al. [43]. 
Statistical analysis. Statistical analyses were 
performed using XLSTAT 2012 software. Continuous 
data were expressed as mean ± standard deviation 
(SEM) and were compared using a one-way, two-way 
ANOVA followed by Tuckey test. Survival was 
compared using Kaplan-Meier test. We considered p 
< 0.05 as statistically significant.  
Results 
Radiolabeling of Tz-1-4 with Lutetium-177  
We first radiolabeled Tz-1 using Method A, 
which requires 20 min heating at 50 °C, affording the 
expected [177Lu]Lu-Tz-1 with high radiochemical 
purity (98%) and molar activity (> 8 GBq/µmol). 
However, this method provided unreproducible 
radiochemical yields (≈ 60-80%, n = 15) after 
purification and formulation due to the formation of 
an unidentified radiolabeled byproduct (Table 1). The 
radiolabeling of Tz-2 according to Method A likewise 
resulted in both low radiochemical yields and purities 
(36% and 24%, respectively), and the method was 
unsuccessful for the radiolabeling of Tz-3 (data not 
shown). Furthermore, the entire radiolabeling process 
of Tz-1 and Tz-2  including HPLC purification and 
formulation  required at least 105 min. 
Subsequently, the room temperature radiolabeling 
method described by Membreno et al. [18] (i.e. Method 
B; which did not involve a purification step) was 
tested and led to improvements in the radiochemical 
yields (79-89% overall yields) and purities (equal or 
superior to 97%) of [177Lu]Lu-Tz-1-4 after formulation 
in only 75 min (Table 1).  
 
 
Figure 1: Comparison of the pharmacokinetic profiles of [177Lu]Lu-Tz-1-3 alone in mice bearing A431-CEA-Luc peritoneal disseminated tumors (i.p. injection). (A) SPECT-CT 
imaging of [177Lu]Lu-Tz-1-3 at 2 h and 24 h p.i. (10 MBq) 21 days post xenograft. (B) %IA/g in organs at 24 h p.i. for [177Lu]Lu-Tz-1-3 (10 MBq). B: bladder, I: intestines. * p < 0.05: 
[177Lu]Lu-Tz-1 vs [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3. (C) %IA in the entire abdomen at 2 h post injection of [177Lu]Lu-Tz-1-3 (10 MBq) using SPECT imaging. * p < 0.05: 
[177Lu]Lu-Tz-1 vs [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3 (One-way ANOVA test). Scale bars: SPECT: Max: 4000 kBq/mL, Min: 700 kBq/mL (2 h) and Max: 2000 kBq/mL, Min: 100 
kBq/mL (24 h); CT: Max: 4000 HU, Min: 400 HU (at both 2 and 24 h). 
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SPECT imaging of [177Lu]Lu-Tz-1-3 alone 
The biodistribution profiles of [177Lu]Lu-Tz-1-3 
were monitored using SPECT imaging at 2 h and 24 h 
after i.p. administration. These data clearly 
demonstrated that without the prior injection of 
35A7-TCO, [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3 have 
different pharmacokinetic profiles than [177Lu]Lu-Tz-1 
(Figure 1A). Indeed, both SPECT imaging and 
radioactivity counting showed exclusively renal 
clearance for [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3, while 
[177Lu]Lu-Tz-1 is primarily eliminated via the liver. In 
addition, [177Lu]Lu-Tz-2 displayed a significantly 
longer circulation time in the blood compared to the 
two other radioligands (at 24 h p.i.: 0.22 ± 0.02 %IA/g 
for [177Lu]Lu-Tz-2 vs 0.02 ± 0.00 %IA/g and 0.03 ± 0.04 
%IA/g for [177Lu]Lu-Tz-1 and [177Lu]Lu-Tz-3, 
respectively) (Figure 1B). In contrast, the longer the 
PEG linker, the more rapidly the Tz-based 
radioligand was eliminated from the peritoneal 
cavity. Indeed, 24 hours after the injection of 
[177Lu]Lu-Tz-1-3, the %IA in the entire abdomen was 
significantly higher for [177Lu]Lu-Tz-1 compared to 
[177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3 (Figure 1C).  
Biodistribution Profiles of [177Lu]Lu-Tz-1-4 
with Prior Injection of 35A7-TCO 
Pretargeted SPECT imaging  performed via the 
i.v. injection of 35A7-TCO, followed 24 h later by the 
i.p. administration of [177Lu]Lu-Tz-1  produced a 
specific signal in peritoneal tumors (Supplementary 
Figure S1). It should be noted that a study using 
[177Lu]Lu-Tz-1 to compare the effect of the injection 
route of 35A7-TCO (i.e. i.v. or i.p.) on the in vivo 
performance of the system was performed and 
resulted in no statistical differences between the two 
different modes of injection (Supplementary Figure 
S1B). Indeed, 48 h after the i.p. administration of 
[177Lu]Lu-Tz-1, the tumoral %IA/g reached maxima 
of 4.07 ± 0.03% and 5.50 ± 0.02%, respectively, with the 
i.v. and i.p. administration of 35A7-TCO.  
Pretargeted biodistribution studies of 
[177Lu]Lu-Tz-1-4 following the injection of 35A7-TCO 
demonstrated variations in the tumoral activity 
concentrations produce by the radioligands, with the 
maximum values for [177Lu]Lu-Tz-2 and 
[177Lu]Lu-Tz-4 occurring at 24 h p.i (6.29 ± 4.27 %IA/g 
and 8.88 ± 5.61 %IA/g, respectively) (Figure 2A-C). 
The tumoral %IA/g using [177Lu]Lu-Tz-2 at both 24 
and 144 h p.i. was significantly higher than that 
obtained with either [177Lu]Lu-Tz-1 and 
[177Lu]Lu-Tz-3 (i.e. 6.29 ± 4.27 % for [177Lu]Lu-Tz-2 vs 
4.00 ± 2.67 % and 3.48 ± 1.20 % for [177Lu]Lu-Tz-1 and 
[177Lu]Lu-Tz-3, respectively, at 24 h p.i.; 3.80 ± 2.18 % 
for [177Lu]Lu-Tz-2 vs 1.50 ± 0.60 % and 1.52 ± 0.93 % 
for [177Lu]Lu-Tz-1 and [177Lu]Lu-Tz-3, respectively, at 
144 h p.i.). However, at each of the three different 
times p.i., no significant difference in the tumoral 
activity concentration was observed between 
[177Lu]Lu-Tz-4 and [177Lu]Lu-Tz-2.  
Dosimetry Corresponding to Pretargeting 
Experiments 
Dosimetry was calculated for self-organ 
irradiation taking into account S-factors computed for 
main organs in the same nude mice species [42].The 
value of the S-factor for small tumors computed by 
the same algorithm was found to be 1.32 Gy/Bq/s 
(Table 2). With respect to pretargeting with 
[177Lu]Lu-Tz-1-4 and 35A7-TCO, the dosimetry values 
obtained for main organs were low, as expected based 
on the biodistribution studies. In PRIT experiments, 
the highest doses to the tumors were provided by 
[177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-4, with 23.692 ± 20.87 
and 25.23 ± 22.38 Gy/40 MBq, respectively.  
Efficiency in PRIT of Peritoneal 
Carcinomatosis Using [177Lu]Lu-Tz-2 and 
35A7-TCO 
Before beginning the PRIT experiment, we 
randomized the mice in order to have similar groups 
in terms of tumor burden (Supplementary Figure S2). 
The bioluminescence imaging follow-up  
performed after the injection of either 40 MBq 
[177Lu]Lu-Tz-2 (with or without prior i.v. injection of 
50 µg of 35A7-TCO 24 hours before) or physiological 
saline NaCl  demonstrated a significant slow-down 
of tumor progression in the mice from the PRIT cohort 
compared to the control cohorts after 13 days (Figure 
3). From 13 to 20 days p.i., the tumors of the PRIT 
groups started to grow again but did so significantly 
more slowly than those of the control groups. In 
addition, the PCI was significantly lower in the mice 
from the PRIT group compared to the control groups 
(i.e. 15.5 ± 2.3 for PRIT group vs 30.0 ± 2.3 and 30.8 ± 
1.4 for NaCl and control [177Lu]Lu-Tz-2, respectively), 
a finding which correlates with the in vivo 
observations (Figure 4).     
Discussion 
Pretargeted radioimmunotherapy based on 
biorthogonal click chemistry has been used for the 
first time in the context of peritoneal carcinomatosis 
using a CEA-targeted 35A7 mAb grafted with TCO 
and several different Tz constructs radiolabeled with 
lutetium-177. Two protocols for radiolabeling were 
used with Tz-1-3. Method A, described by Robillard 
and co-workers, involves a heating step [14]. Despite 
leading to high molar activities and excellent 
radiochemical purities, this 3-step process  
radiolabeling, HPLC purification, and formulation  
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provided moderate and unreproducible 
radiochemical yields due to the formation of an 
unidentified radiolabeled byproduct that necessitated 
a HPLC purification step. The formation of this 
byproduct extended the duration of the synthesis and 
formulation process and led to a loss of the desired 
radiolabeled compound. In contrast, Method B, 
described by Membreno et al. [18], facilitated the quick 
and efficient radiolabeling of Tz-1-4 at room 
temperature with high molar activities, high 
radiochemical yields, and purities. Critically, we did 
not observe the formation of any radiolabeled 
byproducts using Method B. 
 
Figure 2: (A-C) Systematic selection of the most appropriate Tz-bearing radioligand for the PRIT of peritoneal carcinomatosis based on in vivo performance in mice bearing 
peritoneal A431-CEA-Luc disseminated tumors. Peritoneal tumors were first injected i.v. with 50 µg of 35A7-TCO, followed 24 h later by the i.p. injection of [177Lu]Lu-Tz-1-4 
(10 MBq). %IA/g measured in main organs (left) and in peritoneal tumors (right) harvested at 24 (A), 48 (B) and 144 h (C) post injection. * p < 0.05: [177Lu]Lu-Tz-4 vs 
[177Lu]Lu-Tz-3, [177Lu]Lu-Tz-2 vs [177Lu]Lu-Tz-1 and [177Lu]Lu-Tz-2 vs [177Lu]Lu-Tz-3. ** p < 0.005: [177Lu]Lu-Tz-4 vs [177Lu]Lu-Tz-1 and [177Lu]Lu-Tz-4 vs [177Lu]Lu-Tz-3 (Tuckey 
Test). 
Theranostics 2019, Vol. 9, Issue 22 
 
 
http://www.thno.org 
6714 
Table 2: Dosimetry data (Mean + SD) for main organs and peritoneal tumors determined for in vivo pretargeting with [177Lu]Lu-Tz-1-4 
and 35A7-TCO. 
Organs 177Lu S-factors (Gy/Bq/s) Organ Weigth (g) Dosimetry (Gy/ MBq) 
   [177Lu]Lu-Tz-1 [177Lu]Lu-Tz-2 [177Lu]Lu-Tz-3 [177Lu]Lu-Tz-4 
    Mean SD Mean SD Mean SD Mean SD 
Heart  4.66E-11 0.141 1.87E-03 8.74E-04 2.19E-03 7.61E-04 1.00E-03 3.29E-04 3.41E-03 5.38E-04 
Lungs  3.78E-11 0.208 4.37E-03 9.67E-04 3.87E-03 1.19E-03 2.31E-03 2.75E-03 6.41E-03 1.32E-03 
Liver   1.47E-11 1.333 7.56E-02 1.89E-02 1.60E-02 4.76E-03 1.05E-03 3.50E-04 2.06E-02 1.36E-03 
Kidneys  3.95E-11 0.362 2.59E-02 2.52E-03 2.59E-02 2.55E-03 6.62E-03 3.29E-03 2.70E-02 8.25E-04 
Spleen 1.62E-10 0.118 2.30E-02 7.34E-03 2.06E-01 2.06E-02 2.14E-02 1.56E-02 2.56E-02 9.75E-03 
Brain  5.21E-11 0.388 1.16E-03 9.12E-04 7.95E-04 3.38E-04 8.63E-04 1.10E-03 1.13E-03 4.30E-04 
Tumors  1.32E-09 0.016 2.53E-01 1.56E-01 5.92E-01 5.22E-01 1.83E-01 1.13E-01 6.31E-01 5.59E-01 
 
 
 
Figure 3: Longitudinal study of the PRIT of PC using [177Lu]Lu-Tz-2 and 35A7-TCO. After 9 days of tumor growth, mice bearing disseminated A431-CEA-Luc tumors were 
injected with either the treatment or the placebo. Control groups first received an i.v. injection of NaCl followed 24 h later by an i.p. injection of either NaCl or 40 MBq of 
[177Lu]Lu-Tz-2. The PRIT group first received an i.v. injection of 50 µg of 35A7-TCO, followed 24 h later by an i.p. injection of 40 MBq of [177Lu]Lu-Tz-2. Left: In vivo 
bioluminescence imaging at different time points post-treatment. Right: In vivo tumor growth was monitored and quantified from 4 to 20 days post-treatment using 
bioluminescence imaging. *p < 0.05: day 13 and day 20 of PRIT group vs day 13 and 20 of NaCl and [177Lu]Lu-Tz-2 control groups (one-way ANOVA test). 
 
PC is commonly managed by the surgical 
cytoreduction of macroscopic lesions [23] which can 
be accompanied with intraperitoneal chemotherapy 
[19]. The effectiveness of surgery mainly relies on the 
complete removal of tumor tissue, which in turn is 
directly correlated with the ability to visualize 
microscopic lesions. In a previous study, we 
demonstrated the possibility of using fluorescent Tz 
probes to detect PC tumors [37]. Recent developments 
in efficient fluorescent dyes raises the possibility of 
using a TCO/Tz-based system in a per-operatory 
setting as a guide to help surgeons detect microscopic 
lesions [44]. On the other hand, brief intraperitoneal 
RIT  which consists of the i.p. injection of 
radioimmunoconjugates with high molar activity for 
30-60 min, followed by the extensive washing of the 
peritoneal cavity with a saline solution using a 
peristaltic pump  has recently proven effective in 
PC of either colorectal [31] or ovarian [32] origins. 
Pretargeting using the inverse electron demand 
Diels-Alder ligation could thus provide a promising 
theranostic strategy for this disease. In the present 
study, we therefore investigated the efficacy of both 
the pretargeted SPECT and PRIT of PC using 
bioorthogonal click chemistry.  
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Figure 4: Ex vivo determination of the peritoneal carcinomatosis index (PCI) 
according to the score grid developed by Sugarbaker et al. (24) and adapted for 
rodents by Klaver et al. (43). PCI was measured when the maximal ethical disease 
activity index of each mouse was reached. * p < 0.05: PRIT vs both control groups 
(One-way ANOVA test). NB: mice were assigned randomly to the different groups, 
and both tumor growth monitoring and mouse health observations were performed 
in a double-blind manner. 
 
Publications on in vivo pretargeting using the 
TCO/Tz cycloaddition mainly focus on two types of 
radiolabeled tetrazines (i.e. [177Lu]Lu-Tz-3 and 
[177Lu]Lu-Tz-4), with impressive results in both the 
imaging and therapy of subcutaneous models of 
colorectal and pancreatic cancers [12,17,18]. 
Nevertheless, these two types of radioligand differ in 
terms of the Tz structure and the PEG linker length, 
and they have never been assessed in the context of 
disseminated tumors. Because the 
bis(pyridino)-1,2,4,5-tetrazine motif boasts slightly 
better kinetic properties than the 
benzyl-1,2,4,5-tetrazine structure [13,45], we 
synthesized two new derivatives of Tz-3  Tz-1 and 
Tz-2, bearing PEG3 and PEG7 linkers, respectively  
in order to evaluate the pharmacokinetic profiles of 
[177Lu]Lu-Tz-1-3 in vivo and determine the most 
suitable probe for the PRIT of peritoneal 
carcinomatosis. PEGylation is known to improve the 
pharmacokinetic and pharmacodynamic properties of 
(macro)molecules and nano-objects (nanoparticles, 
liposomes, etc.) [46]. Grafting PEG linkers on 
(macro)molecules enhances their aqueous solubility, 
prolongs their circulation times, and can confer 
resistance to uptake and metabolism in the liver [47]. 
In addition, a comparison of the in vivo performance 
of bis(pyridine)-1,2,4,5-tetrazine-based radioligands 
bearing different kind of linkers (i.e. aliphatic chains 
and PEG chains) revealed that constructs with 
lipophilic linkers yielded lower activity concentration 
in tumors, leading to our interest in adding PEG 
linkers on Tz moieties [48]. As the optimal length of 
the PEG linker remains unclear, we evaluated the 
pharmacokinetic influence of linkers of three different 
lengths (PEG3, PEG7, and PEG11). 
To the best of our knowledge, the in vivo 
behavior of [177Lu]Lu-Tz-3 and [177Lu]Lu-Tz-4 has 
never been assessed following i.p. injection. Our 
previous study established the efficacy of i.p. 
injections of Tz for pretargeting with 35A7-TCO in a 
PC model, as the diffusion of the Tz probe is 
facilitated by its small size [37]. We also hypothesized 
that the local i.p. injection of radiolabeled Tz probes 
could induce fewer side effects than a classical i.v. 
route and enhance the retention of the Tz in the 
peritoneal cavity close to the disseminated tumors. 
Consequently, to determine the most effective 
radiolabeled Tz for the PRIT of PC, we first decided to 
compare the biodistribution profiles of 
[177Lu]Lu-Tz-1-3 injected intraperitoneally using 
SPECT imaging and organ radioactivity counting. 
SPECT imaging showed the rapid clearance of 
[177Lu]Lu-Tz-1-3 within a few hours. This comparison 
of [177Lu]Lu-Tz-1-3 also revealed that the length of the 
PEG linker of each Tz-bearing radioligand directly 
influences its in vivo behavior. Indeed, it appeared that 
the shortest linker (i.e. PEG3, [177Lu]Lu-Tz-1) 
promoted the hepatic, intestinal, and renal 
elimination of the radiolabeled probe, while the 
longer linkers (i.e. PEG7 and PEG11, [177Lu]Lu-Tz-2 and 
[177Lu]Lu-Tz-3, respectively) promoted exclusive 
urinary clearance. The retention time of 
[177Lu]Lu-Tz-1 in the peritoneal cavity was longer 
than that of both [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-3. 
This could be explained by the higher lipophilicity of 
[177Lu]Lu-Tz-1. Finally, the high non-specific 
background signal of [177Lu]Lu-Tz-1 in elimination 
organs such as the liver and intestines is a definite 
drawback for imaging in this setting due to the 
possible presence of lesions in these tissues.  
Moving on toward our PRIT study, we have 
already demonstrated the efficacy of the i.v. injection 
of 35A7-TCO immunoconjugates for targeting PC 
[37]. In addition, in biodistribution experiments, we 
noticed that the injection route of 35A7-TCO (i.e. i.v. vs 
i.p.) has no significant influence on the in vivo 
performance of the system, but i.v. injections seem 
more pertinent in the context of the PRIT of PC. 
Hence, biodistributions and PRIT were both 
performed by combining an i.v. injection of 
35A7-TCO with an i.p. injection of [177Lu]Lu-Tz-1-4.  
Next, we wondered if the bis(pyridino)- 
1,2,4,5-tetrazine motif contained in [177Lu]Lu-Tz-1-3  
which was successfully employed by Robillard and 
co-workers  was the most appropriate Tz core 
structure for the PRIT of PC [14]. The pretargeted 
biodistribution profiles of [177Lu]Lu-Tz-1-3 in mice 
bearing PC tumors were compared to that of 
[177Lu]Lu-Tz-4 (a less sterically hindered Tz) to check 
whether the tumor uptake would be significantly 
different with a radioligand boasting a different Tz 
structure [49]. Indeed, [177Lu]Lu-Tz-4 has produced 
impressive results in two different PRIT studies in 
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subcutaneous murine models of pancreatic or 
colorectal cancers (16.8 ± 3.9 %IA/g and 21.2 ± 2.9 
%IA/g in the tumor at 120 h p.i., respectively) [17,18]. 
Moreover, as the chelator in [177Lu]Lu-Tz-4 has an 
additional free carboxylic acid arm compared to that 
in [177Lu]Lu-Tz-1-3, it could facilitate the improved 
coordination of lutetium-177. However, our 
pretargeted biodistribution experiments 
demonstrated similar pharmacokinetic profiles for 
[177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-4. Furthermore, no 
significant activity was found in the bone marrow 
with either Tz. This would suggest that regardless of 
the variant of DOTA used (i.e. three or four carboxylic 
acid moieties), no demetalation occurs in vivo, data 
which are in agreement with that published by 
Läppchen et al. [48]. 
The biodistribution profiles of [177Lu]Lu-Tz-1-4 
administered 24 h after the injection of 35A7-TCO 
clearly demonstrate the potential of TCO/Tz 
pretargeting in the context of PC. The highest tumoral 
activity concentrations were observed with 
[177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-4 (which both contain 
a PEG7 linker), suggesting a close relationship 
between in vivo performance and the hydrophilicity of 
the probe. Along these lines, we hypothesize that in 
the case of i.p. administration, the Tz-based probe 
should be sufficiently soluble to allow access to the 
whole peritoneal cavity but so soluble as to result in 
the overly rapid clearance of the radioligand. 
[177Lu]Lu-Tz-2 seemed more appropriate for 
pretargeting than [177Lu]Lu-Tz-1, which accumulated 
in the liver and exhibited faster peritoneal clearance. 
Indeed, [177Lu]Lu-Tz-1 does not appear to be an 
appropriate radioligand for either pretargeted 
imaging (due to non-specific uptake in the liver and 
intestines) or therapy (due to possible hepatic 
degradation) with 35A7-TCO. Furthermore, the 
tumoral activity concentration values for pretargeting 
with [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-4 were not 
statistically different. As for [177Lu]Lu-Tz-3, it was 
cleared too rapidly and demonstrated poorer in vivo 
performance than [177Lu]Lu-Tz-2, results which led us 
to eschew further in vivo studies with the radioligand.  
The dosimetry calculations from these 
experiments underscore the utility of pretargeting for 
decreasing radiation doses to non-targeted organs. 
Indeed, the radiation dose rates are low for healthy, 
non-target organs and are in the same range as those 
described by other teams [50]. The calculated dose 
was higher in the liver for [177Lu]Lu-Tz-1 than for 
[177Lu]Lu-Tz-2-4 and decreased with increasing PEG 
linker length, data that is generally in agreement with 
both the biodistribution and SPECT imaging 
experiments. With respect to the peritoneal tumors, 
the dose rate was higher for [177Lu]Lu-Tz-2 (0.59 
Gy/MBq) than either [177Lu]Lu-Tz-1 or [177Lu]Lu-Tz-3 
(0.25 and 0.18 Gy/MBq, respectively). As a result, 
[177Lu]Lu-Tz-2 probe was selected for subsequent 
PRIT experiments.  
In the recent publication of Membreno and 
co-workers on the PRIT of subcutaneous CRC, the 
authors assessed increasing doses of [177Lu]Lu-Tz-4 
(i.e. 18.7, 37.0 and 55.5 MBq, i.v. injected) and 
demonstrated a complete survival response 
associated with a significant total tumor regression 
even at the lowest injected dose. In addition, no 
associated toxicity was observed at the highest 
injected dose. Because (i) [177Lu]Lu-Tz-2 is 
administered via i.p. injection, (ii) PC is a very 
aggressive cancer, and (iii) no demonstrations of in 
vivo pretargeting in disseminated tumors has yet been 
published, we selected the median dose of 40 MBq for 
this proof-of-concept PRIT experiment. Tumor 
growth was monitored in vivo for 20 days after 
treatment using bioluminescence imaging and was 
subsequently assessed via the ex vivo determination of 
the PCI [24,43]. The significant tumor growth 
slow-down observed 13 days after the administration 
of [177Lu]Lu-Tz-2 in the PRIT group demonstrated for 
the first time the efficacy of click chemistry-based 
PRIT on disseminated tumors. Those promising 
results encourage us to further optimize this approach 
to PRIT by varying the amount of 35A7-TCO injected, 
changing the dose of radioligand, and performing 
several injections of [177Lu]Lu-Tz-2 [36,18]. 
In conclusion, this is the first demonstration of 
the click chemistry-based pretargeted SPECT and 
PRIT of disseminated tumors. This investigation was 
performed using four different Tz-based radioligands, 
and the best in vivo results were obtained with probes 
containing a PEG linker of intermediate length (i.e. 
PEG7 in [177Lu]Lu-Tz-2 and [177Lu]Lu-Tz-4). Finally, a 
longitudinal therapy study with 35A7-TCO and 
[177Lu]Lu-Tz-2 revealed that PRIT is a promising new 
therapeutic approach for peritoneal carcinomatosis 
from colorectal origin.  
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